Niagen Bioscience, Inc. Common StockNAGE
About: Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Employees: 104
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
644% more call options, than puts
Call options by funds: $1.53M | Put options by funds: $206K
486% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 7
85% more capital invested
Capital invested by funds: $64.3M [Q3] → $119M (+$54.5M) [Q4]
46% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 24
34% more funds holding
Funds holding: 91 [Q3] → 122 (+31) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Raghuram Selvaraju 37% 1-year accuracy 121 / 329 met price target | 41%upside $11 | Buy Reiterated | 8 Apr 2025 |
Financial journalist opinion
Based on 4 articles about NAGE published over the past 30 days





